South Asian diabetic patients have an increased risk of developing vascular complications and microvascular dysfunction has been linked to the development of these diabetic complications. We investigated the effect of 3 months Endocalyx Pro™ supplementation on microvascular health, measured with SDF imaging, in South Asian type 2 diabetic patients in a randomized double-blinded placebo-controlled trial (NCT03889236). The Endocalyx Pro™ group received Endocalyx Pro™ supplement daily for 3 consecutive months, which consists of a mix of fucoidan, glucosamine sulphate, hyaluronic acid, superoxide dismutase and polyphenols. Primary outcome was improvement of microvascular parameters measured with SDF-imaging. In vitro, the inhibitory effect of fucoidan to the heparan sulphate-degrading enzyme heparanase was evaluated. At baseline, clinical parameters or inflammatory markers were within normal ranges for both groups, and were not affected by Endocalyx Pro™ supplementation as evaluated with linear mixed models. Endocalyx Pro™ supplementation improved capillary blood volume, Microvascular Health Score and the perfused boundary region (PBR) compared to the placebo group evaluated with independent T-test. In contrast to the placebo group, no increase in plasma heparanase activity was observed after Endocalyx Pro™ supplementation. In vitro examination showed that Endocalyx Pro’s™ principal component fucoidan dose dependently inhibited heparanase. This study shows that Endocalyx Pro™ preserves microvascular health in South Asian diabetic patients, potentially through the heparanase inhibiting effect of fucoidan.
Related posts
April 10, 2024
